Dr. Jeffrey Cummings (Brain Health) released the fifth annual Alzheimer’s Disease Drug Development Pipeline: 2022 publication. The paper reviews the current pipeline of drugs in clinical trials for the treatment of Alzheimer's disease (AD). It examines an updated view of clinical trials, new drugs, and offers a future outlook on drug development.
The citation examines new facts about all AD drugs, their underlying biology, and the clinical trials developing them. The current outlook shows that there are 143 drugs in the 2022 Alzheimer’s drug development pipeline and 83.2 percent of these treatments are intended for disease modification. 50,575 participants are needed for current Alzheimer’s drug clinical trials.
Clinical trials are the sole means by which new treatments for AD can be approved. Increasing the number of trials, enhancing trial efficiency, and recruiting new participants are critical to advancing new therapeutics for AD.
